Versant Ventures | Activity | F4Versant Ventures Activity
Every public signal F4 has attached to this firm, with sources and cross-entity links.
Exit
Portfolio company Anokion ceased operations (out of business exit).
Anokion
Launched Dayra Therapeutics with $70M total funding including $50M from Biogen partnership for oral macrocyclic peptides.
Investment
Participated in $65M Series B for Gate Bioscience, advancing oral molecular gate medicines for inflammatory and neurological diseases.
Gate Bioscience
Exit
Portfolio company SixPeaks Bio acquired by AstraZeneca for up to $300M to advance obesity treatments with muscle preservation.
SixPeaks Bio AG
4 investments· JAN 2025 – SEP 2025Show all
Investment
Co-led $50M Series A for AllRock Bio to advance ROC-101, a first-in-class ROCK inhibitor for pulmonary hypertension.
AllRock Bio
Investment
Co-led $65M Series A for Dualitas Therapeutics to advance bispecific antibodies for immune and inflammatory disease.
Dualitas Therapeutics
Investment
Led Series A investment in SixPeaks Bio, developing obesity therapeutics with preserved lean muscle mass.
SixPeaks Bio AG
Investment
Co-led $65M Series A for Helicore Biopharma, a GIP antagonist developer focused on obesity therapeutics.
Helicore Biopharma